Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Articles by Staff

I Am an Advocate

Deanna Sanchez Yamamoto, NP  |  

I have never considered myself to be a political person, much less an “advocate,” which is why I was surprised to become an ARHP advocacy committee member.

What a Bold Vision and Dedication Can Achieve

Leslie Crofford, MD  |  

Over the past two years, you have heard us talking a lot about Within Our Reach: Finding a Cure for Rheumatoid Arthritis, the Research and Education Foundation (REF) campaign to raise and award funds for investigator-initiated research to find a cure for rheumatoid arthritis (RA).

Letters to the Editor

  |  

I read with interest Dr. Fox’s perspective in the June issue of The Rheumatologist [TR] regarding ghost writing in medical research. Dr. Fox is all for integrity in research (who isn’t?); nevertheless, he takes to task some of the people (Ross et al and the editors of the Journal of the American Medical Association [JAMA]) who write about the corrupting influence of industry on physicians, including those in academics [JAMA 2008;299(15):1800-1812]. Part of his motivation may be to defend members of ACR who have been involved in the activity of ghostwriting and guest editing. This approach may play well to readers of The Rheumatologist, but it would seem that Dr. Fox should address his concerns to the editors of JAMA. That way, the authors of the article could offer a rebuttal to Dr. Fox’s concerns and assertions, and we all could get closer to the truth about this important issue.

Enact Change in RA

David S. Pisetsky, MD, PhD  |  

Future advances could be challenged by structural barriers within the specialty

Medical Decision Making and Coding

Melesia Tillman, CPC, CCP  |  

In my years of coding for rheumatology, I am often asked this type of question: “I have a patient who recently came in for a visit. She had two or three diagnoses, was placed on three or four different medications, and we ran one or two labs on her. Does this qualify for a level-four visit?”